13 search results for: ige
IgE as a Biomarker for Type 2 Asthma
Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.
Mechanisms of Production and Clinical Impact of IgE
Explore how type 2 inflammation drives the production of IgE in severe asthma
Digestive Disease Week 2024 | Washington D.C.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.
World Digestive Health Day 2024 | May 29
In recognition of World Digestive Health Day, ADVENT is providing medical education resources to increase awareness of eosinophilic esophagitis (EoE).
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
ADVENT at IRS-ISIAN | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Join Profs. Shigeharu Fujieda, Peter Hellings, and Eugenio De Corso for an educational symposium on the evolving understanding of disease control and clinical remission in CRSwNP.
Shigeharu Fujieda, MD, PhD
Professor in the Division of Otorhinolargngology, Head & Neck Surgery | University of Fukui, Matsuoka, Japan
Potential Biomarkers of Subclinical Control in AD Pathophysiology
Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
Type 2 Inflammation Underpins Pediatric Severe Asthma
Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
Charting the Future: Preventing the Atopic March
In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
